title: [HIV and AIDS: what's new in 2010?].
abstract: Antiretroviral therapy is now simpler than ever, with one tablet once daily being the gold standard for the development of new combinations. Indications for treatment initiation have now been extended before moderate immune suppression, taking in account not only the individual benefit, but also the public health aspect of preventing HIV transmission to a sexual partner. New preventing methods have been tested in 2010: microbicides as well as dual antiretroviral treatment in HIV-negative high risk population as a chemoprophylaxis have been published. If these last two tools offer some options for the future, their applicability at a large scale warrant further development.
authors.affiliation: Unite VIH/sida, Service de maladies infectieuses, Département de medecine interne, HUG, 1211 Genève 14.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Calmy
authors.forename: Véronique
authors.initials: V
authors.lastname: Schiffer
authors.forename: Bernard
authors.initials: B
authors.lastname: Hirschel
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D018890:Chemoprevention; D005782:Gels; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D063065:Organophosphonates / Q000627:therapeutic use; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D005782:Gels; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine